Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT

Opelz, 2013, The Collaborative Transplant Study Registry, Transplant Rev, 27, 43, 10.1016/j.trre.2013.01.004

Chambers, 2017, The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart‒lung transplantation report—2017; Focus theme: Allograft ischemic time, J Heart Lung Transplant, 36, 1047, 10.1016/j.healun.2017.07.016

Cooper, 1993, A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts, J Heart Lung Transplant, 12, 713

Estenne, 2002, Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria, J Heart Lung Transplant, 21, 297, 10.1016/S1053-2498(02)00398-4

Meyer, 2014, ISHLT/ATS/ERS BOS Task Force Committee; ISHLT/ATS/ERS BOS Task Force Committee. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome, Eur Respir J, 44, 1479, 10.1183/09031936.00107514

Palmer, 2000, Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation, Chest, 118, 1214, 10.1378/chest.118.4.1214

Gerhardt, 2003, Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study, Am J Respir Crit Care Med, 168, 121, 10.1164/rccm.200212-1424BC

Verleden, 2004, Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation, Transplantation, 77, 1465, 10.1097/01.TP.0000122412.80864.43

Pakhale, 2005, Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation, J Heart Lung Transplant, 24, 1260, 10.1016/j.healun.2004.08.026

Sato, 2011, Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction, J Heart Lung Transplant, 30, 735, 10.1016/j.healun.2011.01.712

Glanville, 2010, Bronchoscopic monitoring after lung transplantation, Semin Respir Crit Care Med, 31, 208, 10.1055/s-0030-1249117

Verleden, 2014, A new classification system for chronic lung allograft dysfunction, J Heart Lung Transplant, 33, 127, 10.1016/j.healun.2013.10.022

Glanville, 2014, CLAD: does the emperor have new clothes?, Am J Transplant, 14, 2681, 10.1111/ajt.12943

Kapila, 2015, Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: a survey, J Heart Lung Transplant, 34, 65, 10.1016/j.healun.2014.09.029

Levine, 2016, Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant, 35, 397, 10.1016/j.healun.2016.01.1223

Glanville, 2017, Physiology of chronic lung allograft dysfunction: back to the future?, Eur Respir J, 49, 10.1183/13993003.00187-2017

Sato, 2013, Progression pattern of restrictive allograft syndrome after lung transplantation, J Heart Lung Transplant, 32, 23, 10.1016/j.healun.2012.09.026

Verleden, 2011, Survival determinants in lung transplant patients with chronic allograft dysfunction, Transplantation, 92, 703, 10.1097/TP.0b013e31822bf790

Sato, 2012, Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation, J Heart Lung Transplant, 31, 354, 10.1016/j.healun.2011.12.015

Todd, 2014, Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction, Am J Respir Crit Care Med, 189, 159, 10.1164/rccm.201306-1155OC

Glanville, 2019, Chronic lung allograft dysfunction: definition and update of restrictive allograft syndrome―a consensus report from the Pulmonary Council of the ISHLT, J Heart Lung Transplant, 38, 483, 10.1016/j.healun.2019.03.008

Ofek, 2013, Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis, Mod Pathol, 26, 350, 10.1038/modpathol.2012.171

Miller, 2005, Standardisation of spirometry, Eur Respir J, 26, 319, 10.1183/09031936.05.00034805

de Wall, 2014, Home spirometry as early detector of azithromycin refractory bronchiolitis obliterans syndrome in lung transplant recipients, Respir Med, 108, 405, 10.1016/j.rmed.2013.12.016

Garfield, 2012, Total lung capacity by plethysmography and high-resolution computed tomography in COPD, Int J Chron Obstruct Pulmon Dis, 7

Dettmer, 2017, CT at onset of chronic lung allograft dysfunction in lung transplant patients predicts development of the restrictive phenotype and survival, Eur J Radiol, 94, 78, 10.1016/j.ejrad.2017.06.008

Verleden, 2016, Predictors of survival in restrictive chronic lung allograft dysfunction after lung transplantation, J Heart Lung Transplant, 35, 1078, 10.1016/j.healun.2016.03.022

Greenland, 2013, Association of large-airway lymphocytic bronchitis with bronchiolitis obliterans syndrome, Am J Respir Crit Care Med, 187, 417, 10.1164/rccm.201206-1025OC

Neurohr, 2009, Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients, J Heart Lung Transplant, 28, 468, 10.1016/j.healun.2009.01.014

Verleden, 2014, Elevated bronchoalveolar lavage eosinophilia correlates with poor outcome after lung transplantation, Transplantation, 97, 83, 10.1097/TP.0b013e3182a6bae2

Mertens, 2011, Bile acids aspiration reduces survival in lung transplant recipients with BOS despite azithromycin, Am J Transplant, 11, 329, 10.1111/j.1600-6143.2010.03380.x

Verleden, 2015, Impact of CLAD phenotype on survival after lung retransplantation: a multicenter study, Am J Transplant, 15, 2223, 10.1111/ajt.13281

Halloran, 2018, Comprehensive outcomes after lung retransplantation: a single-center review, Clin Transplant, 32, e13281, 10.1111/ctr.13281

Vos, 2013, Pirfenidone: a potential new therapy for restrictive allograft syndrome?, Am J Transplant, 13, 3035, 10.1111/ajt.12474

Vos, 2018, Pirfenidone in restrictive allograft syndrome after lung transplantation: a case series, Am J Transplant, 18, 3045, 10.1111/ajt.15019

Suhling, 2016, Nintedanib in restrictive chronic lung allograft dysfunction after lung transplantation, J Heart Lung Transplant, 35, 939, 10.1016/j.healun.2016.01.1220

Kohno, 2011, Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation, Transplant Proc, 43, 1868, 10.1016/j.transproceed.2011.02.007

Fisher, 2005, The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation, Am J Transplant, 5, 537, 10.1111/j.1600-6143.2004.00709.x

Verleden, 2009, Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation, Transplant Proc, 41, 1816, 10.1016/j.transproceed.2009.03.070

Benden, 2017, Therapy options for chronic lung allograft dysfunction‒bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: a systematic review, J Heart Lung Transplant, 36, 921, 10.1016/j.healun.2017.05.030

Yung, 2015, Lung transplantation and extracorporeal photopheresis: the answer to bronchiolitis obliterans?, Transfus Apher Sci, 52, 162, 10.1016/j.transci.2015.02.003

Greer, 2013, Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients, Am J Transplant, 13, 911, 10.1111/ajt.12155

Yates, 2005, Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome, Am J Respir Crit Care Med, 172, 772, 10.1164/rccm.200411-1537OC

Gottlieb, 2008, Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation, Transplantation, 85, 36, 10.1097/01.tp.0000295981.84633.bc

Jain, 2010, Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome, J Heart Lung Transplant, 29, 531, 10.1016/j.healun.2009.12.003

Verleden, 2006, Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome, Am J Respir Crit Care Med, 174, 566, 10.1164/rccm.200601-071OC

Corris, 2015, A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation, Thorax, 70, 442, 10.1136/thoraxjnl-2014-205998

Verleden, 2011, Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study, Transpl Int, 24, 651, 10.1111/j.1432-2277.2011.01248.x

Ruttens, 2018, A proof of concept: addition of montelukast compared to placebo for bronchiolitis obliterans syndrome after lung transplantation, PLoS One, 13, 10.1371/journal.pone.0193564

Gottlieb, 2016, ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients, J Heart Lung Transplant, 35, 213, 10.1016/j.healun.2015.08.012

Vital, 2013, Impact of sinus surgery on pseudomonal airway colonization, bronchiolitis obliterans syndrome and survival in cystic fibrosis lung transplant recipients, Respiration, 86, 25, 10.1159/000339627

Vos, 2011, A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation, Eur Respir J, 37, 164, 10.1183/09031936.00068310

Ruttens, 2016, Prophylactic azithromycin therapy after lung transplantation: post hoc analysis of a randomized controlled trial, Am J Transplant, 16, 254, 10.1111/ajt.13417

Johnson, 2003, Statin use is associated with improved function and survival of lung allografts, Am J Respir Crit Care Med, 167, 1271, 10.1164/rccm.200205-410OC

Li, 2011, Graft-protective effects of the HMG-CoA reductase inhibitor pravastatin after lung transplantation―a propensity score analysis with 23 years of follow-up, Transplantation, 92, 486, 10.1097/TP.0b013e318225670d

Vos, 2017, High-dose vitamin D after lung transplantation: a randomized trial, J Heart Lung Transplant, 36, 897, 10.1016/j.healun.2017.03.008

Glanville, 2015, Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation, J Heart Lung Transplant, 34, 16, 10.1016/j.healun.2014.06.001

Jaksch, 2014, Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study, Am J Transplant, 14, 1839, 10.1111/ajt.12824

Treede, 2012, Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation, J Heart Lung Transplant, 31, 797, 10.1016/j.healun.2012.03.008

Iacono, 2006, A randomized trial of inhaled cyclosporine in lung-transplant recipients, N Engl J Med, 12, 141, 10.1056/NEJMoa043204

Johnson, 2012, Cyclosporine inhalation solution does not improve bronchiolitis obliterans sundrome-free survival following lung transplant: results from the CYCLIST trial, J Heart Lung Transplant, 31, S66, 10.1016/j.healun.2012.01.177

Chambers, 2017, Mesenchymal stromal cell therapy for chronic lung allograft dysfunction: results of a first-in-man study, Stem Cells Transl Med, 6, 1152, 10.1002/sctm.16-0372

Tikkanen, 2015, Functional outcomes and quality of life after normothermic ex vivo lung perfusion lung transplantation, J Heart Lung Transplant, 34, 547, 10.1016/j.healun.2014.09.044

Warnecke, 2018, Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study, Lancet Respir Med, 6, 357, 10.1016/S2213-2600(18)30136-X

Hachem, 2010, Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation, J Heart Lung Transplant, 29, 973, 10.1016/j.healun.2010.05.006

Rosenberger, 2017, Long-term follow-up of a randomized controlled trial evaluating a mobile health intervention for self-management in lung transplant recipients, Am J Transplant, 17, 1286, 10.1111/ajt.14062

Voskrebenzev A, Greer M, Gutberlet M, et al. Detection of chronic lung allograft dysfunction using ventilation-weighted Fourier decomposition MRI. Am J Transplant, in press.

Liu, 2018, Baseline lung allograft dysfunction is associated with impaired survival after double-lung transplantation, J Heart Lung Transplant, 37, 895, 10.1016/j.healun.2018.02.014

Verleden, 2017, “White-out” after lung transplantation: a multicenter cohort description of late acute graft failure, Am J Transplant, 17, 1905, 10.1111/ajt.14268

Jonigk, 2017, Comparative analysis of morphological and molecular motifs in bronchiolitis obliterans and alveolar fibroelastosis after lung and stem cell transplantation, J Pathol Clin Res, 3, 17, 10.1002/cjp2.60

Berastegui, 2017, BALF cytokines in different phenotypes of chronic lung allograft dysfunction in lung transplant patients, Clin Transplant, 31, 10.1111/ctr.12898

Saito, 2014, Distinct expression patterns of alveolar “alarmins” in subtypes of chronic lung allograft dysfunction, Am J Transplant, 14, 1425, 10.1111/ajt.12718

Saito, 2018, Upregulation of alveolar neutrophil enzymes and long pentraxin-3 in human chronic lung allograft dysfunction subtypes, J Thorac Cardiovasc Surg, 155, 2774, 10.1016/j.jtcvs.2018.02.039

Verleden, 2015, Differential cytokine, chemokine and growth factor expression in phenotypes of chronic lung allograft dysfunction, Transplantation, 99, 86, 10.1097/TP.0000000000000269